Compare Ginkgo Bioworks Holdings Inc (DNA) vs Centrus Energy Corp (LEU) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Centrus Energy (LEU) trades at $189.03, down 0.16% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 revenue of $176.1 million, beating expectations, but net income declined to $16.8 million from $28.9 million year-over-year due to higher costs. Recent developments include a $900 million DOE contract and a HALEU supply agreement with X-energy, positioning Centrus as a key player in the nuclear fuel supply chain with a $4.5 billion backlog.

The outlook for LEU is positive given its strategic role in nuclear energy expansion and strong institutional support, but risks include margin compression and execution challenges. Analysts maintain a buy consensus with a $228.50 price target, representing 21% upside potential from current levels.